Breast Cancer Tumor Care Observational Programme

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to investigate efficacy and tolerability under anastrozole (Arimidex) treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Anastrozole

Criteria

Inclusion Criteria:

• Postmenopausal women

• Already on upfront Arimidex Therapy (Start 1-4 weeks before)

• HR+

Exclusion Criteria:

• Premenopausal women

• Tamoxifen switch patients